Previous 10 | Next 10 |
Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biolog...
2023-08-22 09:26:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dragonfly Energy (NASDAQ: DFLI ) stock is taking a beating on Tuesday after the lithium-ion battery company released its second-quarter earnings report . That report sta...
2023-08-22 09:13:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tingo Group (NASDAQ: TIO ) stock is falling on Tuesday after the fintech company announced that it’s delaying the release of its latest earnings report . Accordin...
2023-08-22 08:39:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips G Medical Innovations (NASDAQ: GMVD ) stock is climbing higher on Tuesday without any clear news from the healthcare company . G Medical Innovations hasn’t put ou...
2023-08-22 08:04:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company . There are no new press release...
2023-08-03 10:27:15 ET Axcella Health press release ( NASDAQ: AXLA ): Q2 GAAP EPS of -$0.05. Cash Position: As of June 30, 2023, cash and cash equivalents totaled $8.9 million, compared to $17.1 million as of December 31, 2022. For further details see: Axcell...
2023-05-04 17:33:02 ET Axcella Health press release ( NASDAQ: AXLA ): Q1 GAAP EPS of -$0.05 beats by $0.11 . As of March 31, 2023, cash and cash equivalents totaled $12.5 million, compared to $17.1 million as of December 31, 2022. For further details see: Axc...
Dr. Lucy E.M. Finnigan will present on the Phase 2a clinical trial of AXA1125 in Long COVID Fatigue on April 18 Dr. Finnigan will also report on AXA1125 treatment effects on biomarkers of mitochondrial energetics and vascular endothelial function on April 17 Axcella Therapeutics...
2023-03-30 09:12:40 ET Axcella Health press release ( NASDAQ: AXLA ): Q4 GAAP EPS of -$0.33 misses by $0.04 . As of December 31, 2022, cash and cash equivalents totaled $17.1 million, compared to cash, cash equivalents, and marketable securities of $55.0 million as of ...
Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements Axcella presented at Long COVID forum co-sponsored by BIO and ...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...